Jim Simons Caladrius Biosciences, Inc. Transaction History

Renaissance Technologies LLC

  • $56.7 Billion
  • Q2 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$0.41 - $0.74 $47,654 - $86,010
116,231 Added 7.71%
1,623,580 $861,000
Q1 2022

May 13, 2022
SELL
$0.63 - $1.03 $58,782 - $96,105
-93,306 Reduced 5.83%
1,507,349 $1.09 Million
Q4 2021

Feb 11, 2022
SELL
$0.83 - $1.22 $121,512 - $178,608
-146,400 Reduced 8.38%
1,600,655 $1.35 Million
Q3 2021

Nov 12, 2021
BUY
$1.15 - $1.57 $211,856 - $289,230
184,223 Added 11.79%
1,747,055 $2.13 Million
Q2 2021

Aug 13, 2021
BUY
$1.4 - $1.9 $143,747 - $195,086
102,677 Added 7.03%
1,562,832 $2.52 Million
Q1 2021

May 13, 2021
BUY
$1.44 - $2.89 $596,592 - $1.2 Million
414,300 Added 39.61%
1,460,155 $2.82 Million
Q4 2020

Feb 10, 2021
BUY
$1.39 - $1.87 $164,854 - $221,782
118,600 Added 12.79%
1,045,855 $1.5 Million
Q3 2020

Nov 13, 2020
BUY
$1.6 - $3.0 $109,230 - $204,807
68,269 Added 7.95%
927,255 $1.67 Million
Q2 2020

Aug 13, 2020
BUY
$1.66 - $2.38 $717,139 - $1.03 Million
432,012 Added 101.18%
858,986 $1.53 Million
Q1 2020

May 14, 2020
BUY
$1.21 - $3.47 $18,843 - $54,038
15,573 Added 3.79%
426,974 $769,000
Q4 2019

Feb 13, 2020
BUY
$2.02 - $2.85 $39,491 - $55,717
19,550 Added 4.99%
411,401 $1.03 Million
Q3 2019

Nov 13, 2019
BUY
$2.22 - $2.99 $25,563 - $34,429
11,515 Added 3.03%
391,851 $1.02 Million
Q2 2019

Aug 12, 2019
BUY
$2.25 - $3.6 $146,223 - $233,956
64,988 Added 20.61%
380,336 $867,000
Q1 2019

May 14, 2019
BUY
$3.48 - $5.32 $70,480 - $107,745
20,253 Added 6.86%
315,348 $1.14 Million
Q4 2018

Feb 13, 2019
BUY
$3.49 - $5.77 $1.03 Million - $1.7 Million
295,095 New
295,095 $1.05 Million

About CALADRIUS BIOSCIENCES, INC.

CLBS Quotes by TradingView
  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email